The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of …

2 days ago · In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends …

5 days ago · January 21st 2025. In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking …

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical …

Jan 13, 2025 · The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming …

Feb 3, 2025 · A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, …

Nov 30, 2024 · Market Insights. Skyrizi (risankizumab-rzaa) has officially dethroned Humira (reference adalimumab) as AbbVie’s top seller, less than 2 years after adalimumab biosimilars …

Jan 9, 2025 · The biosimilar market could be accelerated through patent litigation reforms that expedite biosimilar market availability throughout the US, according to a study published in …

Nov 14, 2024 · The Impact of the Interchangeability Designation on Patient Biosimilar Access. On June 20, 2024, the FDA published updated draft guidance titled “Consideration for …

Mar 5, 2024 · The FDA has approved Wyost/Jubbonti (denosumab-bddz; GP2411), the first biosimilar to reference Xgeva/Prolia (denosumab) in the US. 1 The drugs will be used to treat …